Verition Fund Management LLC bought a new stake in shares of GlaxoSmithKline PLC (NYSE:GSK) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 30,141 shares of the pharmaceutical company’s stock, valued at approximately $1,300,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bingham Osborn & Scarborough LLC bought a new stake in GlaxoSmithKline PLC during the 2nd quarter valued at $311,000. 10 15 Associates Inc. raised its position in GlaxoSmithKline PLC by 6.4% during the 1st quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock valued at $10,022,000 after purchasing an additional 14,247 shares in the last quarter. Lincluden Management Ltd. raised its position in GlaxoSmithKline PLC by 1.7% during the 1st quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock valued at $5,095,000 after purchasing an additional 1,990 shares in the last quarter. Anchor Capital Advisors LLC raised its position in GlaxoSmithKline PLC by 9.6% during the 1st quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock valued at $25,858,000 after purchasing an additional 53,894 shares in the last quarter. Finally, Freestone Capital Holdings LLC raised its position in GlaxoSmithKline PLC by 11.9% during the 2nd quarter. Freestone Capital Holdings LLC now owns 94,008 shares of the pharmaceutical company’s stock valued at $4,054,000 after purchasing an additional 10,017 shares in the last quarter. 9.28% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on the company. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, September 21st. Citigroup Inc. lowered GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. BidaskClub lowered GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Finally, Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $44.67.

ILLEGAL ACTIVITY NOTICE: “Verition Fund Management LLC Takes Position in GlaxoSmithKline PLC (GSK)” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.watchlistnews.com/verition-fund-management-llc-takes-position-in-glaxosmithkline-plc-gsk/1630652.html.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down 0.02% on Friday, reaching $41.01. The company had a trading volume of 4,354,724 shares. The firm’s 50 day moving average is $40.33 and its 200 day moving average is $41.58. The firm has a market capitalization of $100.23 billion, a PE ratio of 39.74 and a beta of 1.03. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, equities research analysts expect that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 12th. Shareholders of record on Friday, August 11th were paid a $0.491 dividend. The ex-dividend date of this dividend was Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 4.79%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 198.00%.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.